TrialThe Lancet. Infectious diseases2024

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

William H K Schilling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.